Andrew Cooper
Stock Analyst at Raymond James
(2.44)
# 2,367
Out of 4,868 analysts
140
Total ratings
45.16%
Success rate
-1.17%
Average return
Main Sectors:
Stocks Rated by Andrew Cooper
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| HAE Haemonetics | Reiterates: Strong Buy | $115 → $105 | $70.06 | +49.87% | 9 | May 9, 2025 | |
| MYGN Myriad Genetics | Reiterates: Outperform | $19 → $10 | $5.07 | +97.24% | 5 | May 7, 2025 | |
| FLGT Fulgent Genetics | Reiterates: Outperform | $24 → $25 | $20.30 | +23.15% | 2 | May 5, 2025 | |
| HOLX Hologic | Reiterates: Outperform | $90 → $71 | $63.97 | +10.99% | 12 | May 2, 2025 | |
| RVTY Revvity | Reiterates: Outperform | $145 → $120 | $94.41 | +27.11% | 8 | Apr 29, 2025 | |
| ITGR Integer Holdings | Maintains: Outperform | $145 → $150 | $118.96 | +26.09% | 2 | Apr 25, 2025 | |
| UFPT UFP Technologies | Initiates: Market Perform | n/a | $240.25 | - | 1 | Mar 28, 2025 | |
| GH Guardant Health | Reiterates: Outperform | $39 → $59 | $50.57 | +16.67% | 3 | Feb 21, 2025 | |
| AVTR Avantor | Reiterates: Outperform | $26 → $24 | $13.29 | +80.59% | 14 | Feb 10, 2025 | |
| TMO Thermo Fisher Scientific | Reiterates: Outperform | $650 → $667 | $392.56 | +69.91% | 6 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $194.44 | - | 8 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $52.34 | - | 8 | Sep 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $19.03 | - | 16 | May 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Outperform | $68 → $85 | $170.98 | -50.29% | 5 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Outperform | $100 → $76 | $28.33 | +168.27% | 12 | Feb 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $3.07 | - | 1 | Jul 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $29.94 | - | 1 | Jul 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $6.95 | - | 14 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $26.82 | - | 8 | Jan 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $2.89 | - | 5 | Sep 22, 2021 |
Haemonetics
May 9, 2025
Reiterates: Strong Buy
Price Target: $115 → $105
Current: $70.06
Upside: +49.87%
Myriad Genetics
May 7, 2025
Reiterates: Outperform
Price Target: $19 → $10
Current: $5.07
Upside: +97.24%
Fulgent Genetics
May 5, 2025
Reiterates: Outperform
Price Target: $24 → $25
Current: $20.30
Upside: +23.15%
Hologic
May 2, 2025
Reiterates: Outperform
Price Target: $90 → $71
Current: $63.97
Upside: +10.99%
Revvity
Apr 29, 2025
Reiterates: Outperform
Price Target: $145 → $120
Current: $94.41
Upside: +27.11%
Integer Holdings
Apr 25, 2025
Maintains: Outperform
Price Target: $145 → $150
Current: $118.96
Upside: +26.09%
UFP Technologies
Mar 28, 2025
Initiates: Market Perform
Price Target: n/a
Current: $240.25
Upside: -
Guardant Health
Feb 21, 2025
Reiterates: Outperform
Price Target: $39 → $59
Current: $50.57
Upside: +16.67%
Avantor
Feb 10, 2025
Reiterates: Outperform
Price Target: $26 → $24
Current: $13.29
Upside: +80.59%
Thermo Fisher Scientific
Feb 3, 2025
Reiterates: Outperform
Price Target: $650 → $667
Current: $392.56
Upside: +69.91%
Feb 3, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $194.44
Upside: -
Sep 26, 2024
Reiterates: Market Perform
Price Target: n/a
Current: $52.34
Upside: -
May 13, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $19.03
Upside: -
Feb 20, 2024
Downgrades: Outperform
Price Target: $68 → $85
Current: $170.98
Upside: -50.29%
Feb 14, 2024
Downgrades: Outperform
Price Target: $100 → $76
Current: $28.33
Upside: +168.27%
Jul 19, 2023
Initiates: Market Perform
Price Target: n/a
Current: $3.07
Upside: -
Jul 19, 2023
Initiates: Market Perform
Price Target: n/a
Current: $29.94
Upside: -
May 16, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $6.95
Upside: -
Jan 18, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $26.82
Upside: -
Sep 22, 2021
Downgrades: Market Perform
Price Target: n/a
Current: $2.89
Upside: -